Target Expression Landscape: TROP2 vs. HER2-Low in TNBC
The addressable patient population for each ADC class is determined, before any clinical consideration, by how broadly and uniformly the target antigen is expressed across TNBC tumours. TROP2 and HER2-low represent opposite ends of that spectrum — one near-universal, the other restricted and heterogeneous — and this single biological fact cascades into every downstream clinical decision.
TROP2: a near-universal TNBC target
TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein overexpressed in more than 90% of TNBC tumours. A tissue microarray study analysing 18,563 tumours found TROP2 positivity — defined as moderate to strong membranous staining — in 91% of TNBC cases, with 77% showing strong 3+ expression. The expression pattern is predominantly membranous and relatively homogeneous within individual tumours. Functionally, TROP2 promotes cell proliferation, invasion, and self-renewal through calcium signalling; high expression correlates with poor prognosis and early relapse in TNBC. Critically for ADC delivery, TROP2 undergoes constitutive internalisation and recycling, ensuring reliable payload transport into the cell.
TROP2 is overexpressed in 90–95% of TNBC tumours, with 77% demonstrating strong (3+) membranous expression in a tissue microarray study of 18,563 tumours, making TROP2 a near-universal therapeutic target in this breast cancer subtype.
HER2-low: restricted prevalence and mosaic expression
HER2-low status — defined as IHC 1+ or IHC 2+/ISH-negative — represents a newly recognised category distinct from HER2-positive (IHC 3+ or IHC 2+/ISH+) and HER2-zero (IHC 0) disease. Approximately 50–60% of traditionally "HER2-negative" breast cancers fall into the HER2-low category, including a substantial proportion of TNBC. Unlike TROP2, HER2-low expression is characterised by low-level, heterogeneous distribution with significant intratumoral and intertumoral variability — antigen-positive and antigen-negative cell populations coexist in a mosaic pattern within the same tumour. This heterogeneity was the central reason HER2-low disease was historically excluded from HER2-targeted therapy, until the DESTINY-Breast04 trial demonstrated that Trastuzumab Deruxtecan's potent bystander killing could overcome it.
HER2-low status (IHC 1+ or IHC 2+/ISH-negative) was historically classified as "HER2-negative" and excluded from HER2-targeted therapy. DESTINY-Breast04 was the first Phase 3 trial to demonstrate statistically significant benefit from a HER2-directed therapy in this population, establishing HER2-low as a clinically actionable biomarker category.
Linker-Payload Architecture: How Molecular Design Shapes Drug Behaviour
The three ADCs share the same payload class — topoisomerase I inhibitors — but differ fundamentally in linker chemistry, drug-to-antibody ratio, and payload membrane permeability. These differences are not incremental; they produce qualitatively distinct pharmacological behaviours that explain divergent toxicity profiles and, ultimately, divergent clinical outcomes.
Sacituzumab Govitecan: CL2A-SN-38
Sacituzumab Govitecan (SG) conjugates a humanised anti-TROP2 IgG1κ antibody (hRS7) to SN-38 — the active metabolite of irinotecan and a potent topoisomerase I inhibitor — via the CL2A linker, a pH-sensitive hydrolysable linker. The drug-to-antibody ratio (DAR) is approximately 7.6, among the highest of approved ADCs. The CL2A linker is cleaved by acidic pH in lysosomes and by carboxylesterases, enabling rapid intracellular SN-38 release (approximately 90 minutes to peak concentration). However, the linker is relatively unstable in circulation, leading to premature payload release and systemic SN-38 exposure — the primary driver of SG's characteristic toxicity profile, including Grade ≥3 neutropenia in 51% of patients and Grade ≥3 diarrhoea in 10%.
Datopotamab Deruxtecan: GGFG-DXd (DAR ~4)
Datopotamab Deruxtecan (Dato-DXd) conjugates a humanised anti-TROP2 IgG1 antibody to deruxtecan (DXd), an exatecan derivative and topoisomerase I inhibitor, via the GGFG tetrapeptide-based cleavable linker. The DAR is approximately 4 — lower than SG. The GGFG linker is cleaved selectively by lysosomal cathepsins (cathepsin B, cathepsin L), which are enriched in tumour cells. This selectivity produces a linker that is highly stable in plasma, minimising premature payload release and reducing systemic toxicity compared to SG. DXd's high membrane permeability is the key pharmacological advantage: once released intracellularly, DXd diffuses across cell membranes into adjacent tumour cells, enabling bystander killing of TROP2-negative neighbours.
Trastuzumab Deruxtecan: GGFG-DXd (DAR ~8)
Trastuzumab Deruxtecan (T-DXd) uses an identical GGFG tetrapeptide linker and DXd payload as Dato-DXd, but is conjugated to trastuzumab (anti-HER2) with a higher DAR of approximately 8. This elevated drug loading contributes to T-DXd's superior cytotoxic potency but also increases the risk of interstitial lung disease (ILD), which occurs in 12–15% of patients. Cathepsin L is particularly critical for T-DXd linker cleavage in HER2-low tumours — and, as detailed in the next section, cathepsin L secreted into the extracellular space amplifies bystander killing beyond what intracellular release alone can achieve.
Explore the full patent landscape for ADC linker-payload systems and next-generation conjugate designs in PatSnap Eureka.
Search ADC Patents in PatSnap Eureka →Bystander Killing: The Mechanism That Determines Heterogeneity Tolerance
Bystander killing — the capacity of an ADC to eliminate antigen-negative tumour cells adjacent to antigen-positive cells — is not a secondary benefit; in heterogeneous tumours like HER2-low TNBC, it is the primary efficacy mechanism. The three ADCs differ profoundly in how, and how effectively, they achieve this effect.
Trastuzumab Deruxtecan achieves bystander killing through two distinct mechanisms: intracellular DXd release followed by membrane diffusion into adjacent cells, and extracellular cathepsin L-mediated cleavage of the GGFG linker, which releases free DXd directly into the tumour microenvironment to kill HER2-negative bystander cells.
SN-38, the payload of Sacituzumab Govitecan, has moderate membrane permeability. Once released inside a TROP2-positive cell, it can diffuse into immediately adjacent cells, but the bystander effect is restricted to cells in close proximity. In tumours with significant TROP2-negative cell populations, this limitation creates a meaningful efficacy gap.
DXd, the shared payload of both Dato-DXd and T-DXd, is highly lipophilic and membrane-permeable, enabling more extensive diffusion into neighbouring cells after intracellular release. For T-DXd, a landmark mechanistic study identified an additional and particularly potent pathway: cathepsin L secreted into the extracellular space can cleave the GGFG linker of T-DXd molecules that have not yet been internalised, releasing free DXd directly into the tumour microenvironment. This creates a "field effect" that kills HER2-negative cells throughout the tumour — a mechanism that partially explains T-DXd's exceptional efficacy in HER2-low disease despite minimal target expression. According to peer-reviewed research indexed in databases including PubMed, this extracellular cathepsin L pathway represents a qualitatively distinct mechanism not observed with conventional ADCs.
"Cathepsin L secreted into the extracellular space can cleave T-DXd, releasing DXd outside cells and enabling bystander killing of HER2-negative/low neighbouring cells — a critical mechanism for efficacy in heterogeneous HER2-low tumours."
Research presented at a major oncology meeting demonstrated that cathepsin L secreted into the extracellular space can cleave the GGFG linker of T-DXd, releasing free DXd into the tumour microenvironment. This mechanism is particularly critical in HER2-low TNBC, where target expression is minimal and heterogeneous, and substantially distinguishes T-DXd's bystander killing potency from that of Dato-DXd, despite both using the GGFG-DXd platform.
For Dato-DXd, the GGFG linker is cleaved by intracellular cathepsins, and bystander killing occurs via DXd membrane diffusion after intracellular release. This is more potent than SG's SN-38-mediated bystander effect, but does not benefit from the extracellular cathepsin L amplification seen with T-DXd. Dato-DXd's superior bystander killing compared to SG partially overcomes resistance driven by TROP2 heterogeneity — but the extracellular cathepsin L mechanism remains unique to T-DXd in the current evidence base.
Clinical Efficacy in TNBC: ASCENT, TROPION-PanTumor01, and DESTINY-Breast04
Translating molecular architecture into clinical outcomes requires comparing trials with different patient populations, lines of therapy, and comparator arms — a comparison that demands careful interpretation rather than direct head-to-head reading. The available data nonetheless reveal meaningful efficacy gradients that align with the mechanistic predictions above.
Sacituzumab Govitecan — ASCENT (Phase 3)
The Phase 3 ASCENT trial (NCT02574455) randomised patients with relapsed/refractory metastatic TNBC after two or more prior therapies to SG (10 mg/kg IV, Days 1 and 8 of 21-day cycles) versus physician's choice chemotherapy. The patient population was heavily pretreated — median 4 prior anticancer regimens, including taxanes, anthracyclines, and platinum agents. SG achieved a median PFS of 5.6 months versus 1.7 months with chemotherapy (HR 0.41, 95% CI 0.32–0.52, p<0.0001), a median OS of 12.1 months versus 6.7 months (HR 0.48, 95% CI 0.38–0.59, p<0.0001), and an ORR of 35% versus 5%. The clinical benefit rate was 45% versus 9%, and complete responses occurred in 4% of SG-treated patients.
In the Phase 3 ASCENT trial, Sacituzumab Govitecan achieved a median PFS of 5.6 months versus 1.7 months with chemotherapy (HR 0.41, p<0.0001) and a median OS of 12.1 months versus 6.7 months (HR 0.48, p<0.0001) in heavily pretreated metastatic TNBC, with an ORR of 35% versus 5%.
Datopotamab Deruxtecan — TROPION-PanTumor01 (Phase 1)
TROPION-PanTumor01 (NCT03401385) evaluated Dato-DXd (6 mg/kg or 8 mg/kg IV every 3 weeks) in advanced solid tumours including a TNBC cohort of 44 patients, with a median of 3 prior therapies in the metastatic setting. In the overall TNBC cohort, ORR was 34% (confirmed CR/PR in 32%), with a disease control rate of 77% and median PFS of 4.3–8.2 months across dose cohorts. The most clinically significant finding was the ORR in topoisomerase I-naïve patients (n=27): 52%, versus 34% overall. Given that 30% of the enrolled patients had prior topoisomerase I-based ADC exposure, this difference directly quantifies the cross-resistance penalty between SG and Dato-DXd — a finding with immediate implications for treatment sequencing.
Trastuzumab Deruxtecan — DESTINY-Breast04 (Phase 3)
DESTINY-Breast04 (NCT03734029) randomised patients with HER2-low (IHC 1+ or IHC 2+/ISH-negative) unresectable or metastatic breast cancer — including a TNBC subset — to T-DXd (5.4 mg/kg IV every 3 weeks) versus physician's choice chemotherapy, after 1–2 prior lines of chemotherapy in the metastatic setting. T-DXd achieved a median PFS of 10.1 months versus 5.4 months with chemotherapy (HR 0.51, 95% CI 0.40–0.64, p<0.0001) and a median OS of 23.9 months versus 17.5 months (HR 0.64, 95% CI 0.40–0.86, p=0.003) in the overall HER2-low population. DESTINY-Breast04 was the first Phase 3 trial to demonstrate that a HER2-directed therapy can provide statistically significant and clinically meaningful benefit in HER2-low metastatic breast cancer — a population historically considered "HER2-negative" and excluded from HER2-targeted treatment.
In DESTINY-Breast04, Trastuzumab Deruxtecan achieved a median PFS of 10.1 months versus 5.4 months with chemotherapy (HR 0.51, p<0.0001) and a median OS of 23.9 months versus 17.5 months (HR 0.64, p=0.003) in HER2-low metastatic breast cancer — the first Phase 3 demonstration of benefit from a HER2-directed therapy in this previously "HER2-negative" population.
Map the full clinical trial landscape for ADCs in TNBC — efficacy data, patient populations, and emerging combinations — using PatSnap Eureka.
Explore ADC Clinical Data in PatSnap Eureka →Resistance Mechanisms: Divergent Pathways and Cross-Resistance Risks
The resistance profiles of the three ADCs are shaped by their distinct molecular architectures — but they are not entirely independent. Because all three deliver topoisomerase I inhibitors, certain resistance mechanisms are shared, creating clinically significant cross-resistance that constrains sequential ADC use.
Sacituzumab Govitecan resistance
Five primary resistance mechanisms have been identified for SG. First, UGT1A1-mediated glucuronidation converts SN-38 to inactive SN-38 glucuronide (SN-38G); tumours with high UGT1A1 expression may exhibit intrinsic resistance through rapid SN-38 inactivation, while the UGT1A1*28 polymorphism (reduced UGT1A1 activity) increases toxicity risk. Second, ABCG2 (BCRP, breast cancer resistance protein) actively effluxes SN-38 from cancer cells; preclinical models show that ABCG2 inhibitors such as elacridar can restore sensitivity, a finding supported by patent filings describing combination strategies. Third, loss of TROP2 surface expression or defects in receptor internalisation reduce ADC uptake — epigenetic silencing or TROP2 ectodomain shedding may contribute to acquired resistance. Fourth, point mutations in TOP1 reduce SN-38 binding affinity. Fifth, SN-38's moderate membrane permeability restricts bystander killing, making SG more susceptible to resistance driven by TROP2-negative cell populations within heterogeneous tumours.
Datopotamab Deruxtecan resistance
Cross-resistance with SG is the most clinically immediate resistance concern for Dato-DXd. Both agents deliver topoisomerase I inhibitors; the TROPION-PanTumor01 data — 52% ORR in topoisomerase I-naïve patients versus 34% overall — directly quantifies this cross-resistance in a clinical setting. Shared mechanisms include TOP1 mutations, efflux pump upregulation, and DNA repair pathway activation. Additionally, reduced cathepsin B/L activity in tumour lysosomes impairs GGFG linker cleavage and DXd release — a mechanism not relevant to SG. TROP2 downregulation and multidrug resistance transporter upregulation (P-glycoprotein, ABCG2) also contribute. Research published in peer-reviewed journals indexed by NIH databases suggests that epigenetic upregulation of TROP2 via HDAC inhibitors may restore sensitivity, as may SLFN11 upregulation, which sensitises cells to topoisomerase I inhibitors.
Trastuzumab Deruxtecan resistance
T-DXd resistance is driven by five primary mechanisms. HER2 expression loss through transcriptional silencing, epigenetic modification, or clonal selection of HER2-negative cells is particularly consequential in HER2-low tumours where baseline expression is already minimal. Impaired cathepsin L or cathepsin B activity in lysosomes reduces GGFG linker cleavage — and critically, tumours with low cathepsin L secretion into the extracellular space exhibit reduced bystander killing. Multidrug resistance transporter upregulation (ABCB1, ABCG2) reduces intracellular DXd accumulation, though DXd's membrane permeability partially mitigates this compared to T-DM1's maytansinoid payload. TOP1 mutations and compensatory activation of alternative DNA repair pathways (homologous recombination, base excision repair) constitute the fourth and fifth mechanisms, respectively. Guidelines from organisations including ESMO and NCCN are evolving to address biomarker-guided patient selection for T-DXd, including cathepsin L as an emerging (not yet clinically validated) predictive biomarker.
"Datopotamab Deruxtecan achieved an ORR of 52% in topoisomerase I-naïve TNBC patients, versus 34% overall — a 18-percentage-point gap that directly quantifies the cross-resistance penalty from prior Sacituzumab Govitecan exposure."
Because Sacituzumab Govitecan and Datopotamab Deruxtecan both deliver topoisomerase I inhibitors, patients progressing on SG carry a meaningful cross-resistance burden when transitioning to Dato-DXd. Shared mechanisms include TOP1 mutations, ABCG2 efflux pump upregulation, and DNA repair pathway activation. This cross-resistance is less relevant when transitioning to T-DXd in HER2-low patients, as T-DXd's antibody target, bystander mechanism, and resistance drivers are partially distinct.
Safety Profiles and Sequencing Strategy
The toxicity signatures of the three ADCs reflect their linker stability differences as directly as their efficacy profiles. The CL2A linker's relative instability in circulation drives SG's high systemic SN-38 exposure and its characteristic haematologic and gastrointestinal toxicities; the GGFG linker's plasma stability reduces these systemic effects for Dato-DXd and T-DXd, but T-DXd's higher DAR and DXd's lung tropism produce a distinct ILD risk that requires separate management.
Comparative toxicity
| Adverse event | Sacituzumab Govitecan | Datopotamab Deruxtecan | Trastuzumab Deruxtecan |
|---|---|---|---|
| Grade ≥3 neutropenia | 51% | 38–45% | 19–26% |
| Grade ≥3 diarrhoea | 10% | 4–8% | <5% |
| Interstitial lung disease (ILD) | Rare (<1%) | 3–5% | 12–15% (grade 5: 0.8–2.7%) |
| Dose reductions | 20–25% | 15–20% | 15–20% |
| Discontinuation due to AEs | 4.7% | 5–8% | 10–15% |
For SG, prophylactic G-CSF and aggressive antidiarrhoeal management are essential. UGT1A1 genotyping is recommended before treatment initiation to identify patients at elevated risk of severe toxicity from the UGT1A1*28 polymorphism. For T-DXd, ILD/pneumonitis is the dose-limiting toxicity: it occurs in 12–15% of patients, with grade 5 (fatal) events in 0.8–2.7%. Vigilant monitoring for respiratory symptoms and prompt intervention are mandatory. Dato-DXd offers improved tolerability compared to both, with lower neutropenia and diarrhoea rates than SG and lower ILD risk than T-DXd.
Proposed sequencing in TNBC
Based on available efficacy, safety, and cross-resistance data, a biomarker-guided sequencing framework can be proposed. In patients with metastatic TNBC requiring ADC therapy, Sacituzumab Govitecan is supported by Phase 3 ASCENT data as an established option after two or more prior therapies; ASCENT-03 and combination data with pembrolizumab (ASCENT-04/KEYNOTE-D19, which reported positive PFS results) support exploration in earlier lines. For HER2-low TNBC patients (approximately 50–60% of the TNBC population), Trastuzumab Deruxtecan represents a distinct mechanistic option supported by DESTINY-Breast04 Phase 3 data, with a partially non-overlapping resistance profile. Datopotamab Deruxtecan is most effective in topoisomerase I-naïve patients; its use after SG progression is associated with meaningful cross-resistance, limiting its utility in that sequence. Accurate HER2-low IHC testing — with central confirmation recommended — is essential to identify T-DXd-eligible patients. TROP2 expression testing, while not strictly required given the near-universal expression in TNBC, may provide additional prognostic information. Cathepsin L expression is an emerging but not yet clinically validated biomarker for T-DXd efficacy. The PatSnap life sciences intelligence platform provides patent and literature surveillance tools that can support biomarker strategy development across this rapidly evolving ADC landscape.